Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus rating of “Hold” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $10.78.

A number of analysts have recently issued reports on ZNTL shares. Oppenheimer reissued an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday, August 12th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price for the company in a research report on Monday, August 12th. Finally, UBS Group lowered shares of Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $28.00 to $5.00 in a research report on Thursday, June 20th.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $2.98 on Thursday. The firm has a fifty day moving average price of $3.33 and a 200-day moving average price of $6.96. The stock has a market cap of $211.91 million, a PE ratio of -1.10 and a beta of 1.70. Zentalis Pharmaceuticals has a 1 year low of $2.83 and a 1 year high of $19.14.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same period in the previous year, the firm earned ($1.85) EPS. On average, research analysts expect that Zentalis Pharmaceuticals will post -3.02 EPS for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of ZNTL. Birchview Capital LP bought a new position in Zentalis Pharmaceuticals during the fourth quarter valued at $242,000. Los Angeles Capital Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth about $606,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth about $680,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 66.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 13,634 shares of the company’s stock worth $215,000 after acquiring an additional 5,446 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 12.2% in the 1st quarter. Commonwealth Equity Services LLC now owns 60,895 shares of the company’s stock worth $960,000 after acquiring an additional 6,640 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.